NCT00493454View on ClinicalTrials.gov

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Lymphoma

Interventions

DRUG

Zevalin

.3 mCi IV Over 10 Minutes x 1 Day

DRUG

Rituximab

250 mg/m\^2 IV Over 6 to 8 Hours

DRUG

^111 In Ibritumomab Tiuxetan

1.6 mg IV Over 10 Minutes x 1 Day

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biogen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00493454 - Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas | Biotech Hunter | Biotech Hunter